Phase I Study of Tolerance and Pharmacokinetics of AL2846 in Patients With Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 08 Jan 2018
At a glance
- Drugs AL 2846 (Primary)
- Indications Liver cancer; Lung cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 03 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 03 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 20 Jun 2016 Status changed from not yet recruiting to recruiting.